News

Ophthalmic World Leaders (OWL) will be hosting an OWL Connect event during the American-European Congress of Ophthalmic Surgery (AECOS) 2022 Summer Symposium, Saturday, July 9.

The study investigates 3-year intravitreal implant in eyes with active noninfectious posterior uveitis.

The research from eye care nonprofit Orbis International focuses on diabetic retinopathy in Rwanda, where associated vision complications from diabetes are growing.

The systems could be in the hands of surgeons in the third quarter through a targeted initial launch, according to the company.

According to investigators, a key reason for the link may lie in circadian “clocks,” the molecular machinery within every cell of every organism, which have evolved to adapt to daily stresses, such as changes in light and temperature caused by the rising and setting of the sun.

The company announced it has received FDA IND clearance for linsitinib and prepares to initiate Phase 2b clinical trial.

The research is the result of a national collaboration led by investigators from the Centre for Eye Research Australia at the University of Melbourne and University of Tasmania and the Garvan Institute of Medical Research.

The CLEAR Act would clarify the FDA’s authority to regulate products, including eye drops, after a court decision created unnecessary confusion and turmoil.

John Cooksey, who had an ophthalmology practice in Monroe, Louisiana, served three terms in the US House of Representatives. He also founded an eye clinic in Kenya.

Study demonstrates results of pegcetacoplan as a geographic atrophy therapy.

As special pandemic rules end, a new analysis shows the potential impact on patients in some states and rural areas of others.

A team of investigators is researching the use of a new cell delivery method to help cells stick and stay where they are needed most.

Scientists have revived light-sensing neuron cells in organ donor eyes and restored communication between them as part of a series of discoveries that stand to transform brain and vision research.

Physicians can use navigational tools to attain a much more immersive perspective.

With clearer imaging and enhanced resolution, the new OCT approach could improve medical diagnostic imaging.

The rare disorder is often a delayed or misdiagnosed condition, resulting in unnecessary referrals and imaging.

According to the study by a team of researchers from the University of California Irvine and University of Southern California, treatment with Humanin G reduced protein levels of inflammation markers that become elevated in age-related macular degeneration.

On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss the current status of eye stroke evaluations for CRAO.

Vision Buddy is offering a headset that features modes for TV/movie streaming, magnification, and reading, helping the visually impaired improve their quality of life.

The companies are marketing the first FDA-approved ophthalmology biosimilar as a treatment option for patients with retinal disorders.

Study zeroes in on the sustained mechanism of action of the therapeutic.

According to the company, the AI platform can predict a person's risk of having a stroke or a heart attack in the next five years.

Ophthalmic World Leaders (OWL) invites members of the ophthalmic community who are based near Fort Worth, Texas, to celebrate the launch of its new chapter in Texas.

According to Novartis, the approval is based on year 1 data from the Phase III KESTREL and KITE clinical trials investigating brolucizumab-dbll 6 mg vs aflibercept 2 mg in diabetic macular edema patients.

The company noted that pegcetacoplan, designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases, was granted Fast Track designation by the FDA for the treatment of geographic atrophy.

The study will investigate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in subjects with neovascular age-related macular degeneration.

The study assess retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.

Outlook Therapeutics initially filed the BLA fin March or the use of bevacizumab-vikg in the treatment of wet AMD. The company said it wlll re-submit a revised BLA by September.